Clinical Trial: A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

U.S., April 26 -- ClinicalTrials.gov registry received information related to the study (NCT06945419) titled 'A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes' on April 18.

Brief Summary: The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body.

Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 9 visits.

Study Start Date: April, 2025

Study Type: INTERVENTIONAL

Condition: Healthy Overweight Obesity Type 2 Diabetes

Intervention: DRUG: LY4086940

Administered orally

DRUG: P...